<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03155412</url>
  </required_header>
  <id_info>
    <org_study_id>16-14048S</org_study_id>
    <nct_id>NCT03155412</nct_id>
  </id_info>
  <brief_title>Adipose Tissue Expandability and Type 2 Diabetes</brief_title>
  <acronym>LIMEX</acronym>
  <official_title>Limited Adipose Tissue Expandability as a Risk Factor for Development of Type 2 Diabetes: the Role of Preadipocytes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the study is to analyze deviations in adipogenic potential and metabolic
      properties of preadipocytes in subjects with genetic predisposition to type 2 diabetes, and
      thus identify factors that underlie hypertrophic growth of adipose tissue associated with the
      development of this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adipose tissue (AT) expands in response to excessive energy intake by hyperplasia or
      hypertrophy. While hyperplasia is associated with preservation of insulin sensitivity,
      hypertrophic AT exerts a number of metabolic defects. The mechanisms by which hyperplasia is
      suppressed at the expense of AT hypertrophy remain unknown, but it is expected that the
      hypertrophy of adipocytes is primarily driven by insufficient recruitment and differentiation
      of available preadipocytes. The limitation of hyperplasia occurs already in non-obese healthy
      subjects who are genetically predisposed to Type 2 Diabetes. Using these and control
      subjects, the LIMEX project aims to analyze the mechanisms of AT expandability. The project
      will combine in vivo characterization of AT and in vitro studies on human preadipocytes
      derived from AT biopsies obtained during clinical study. In vitro, proliferation,
      adipogenesis and lipogenesis of adipose cells will be monitored and these properties will be
      related to the degree of AT hypertrophy in vivo, insulin sensitivity and genetic
      predisposition to metabolic complications.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adipogenic capacity of preadipocytes</measure>
    <time_frame>3 months from the establishment of the cell culture</time_frame>
    <description>proliferation assays, messenger ribonucleic acid (mRNA) gene expression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>3 hours investigation of the subject at the start of the study</time_frame>
    <description>Glucose disposal measured by hyperinsulinemic-euglycemic clamp</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>2 hours investigation of the subject at the start of the study</time_frame>
    <description>Oral glucose tolerance test (OGTT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid metabolism</measure>
    <time_frame>3 months from the establishment of the cell culture</time_frame>
    <description>Lipolysis, lipogenesis in cell cultures of adipocytes derived from the subjects</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Offspring of type 2 diabetic patients</arm_group_label>
    <description>Group 1: 25 healthy lean men (age 30-45, BMI &lt;28) with genetic predisposition for type 2 diabetes mellitus (T2DM) - i.e. their two first-degree relatives (parents, siblings) or one first-degree relative and two second-degree relatives with type 2 diabetes (grandparents, uncle, aunt) were diagnosed with T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <description>Group 2: 25 healthy lean men (age 30-45, BMI &lt;28) without any family history of T2DM. Exclusion criteria: any prior history of obesity, elevated triglyceride concentration, hypertension, thyroid or other endocrine disease, smoking, drug abuse. Subjects matched for BMI, fat mass and age to subjects in Group 1 will be recruited.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      adipose tissue plasma / serum preadipocytes (cells)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 healthy lean men (age 30-45, BMI &lt;26). Two groups of subjects (n=25) matched for BMI,
        fat mass and age.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy non-obese men

          -  subject has genetic predisposition for T2DM- i.e. two first-degree relatives (parents,
             siblings) or one first-degree relative and two second-degree relatives with type 2
             diabetes (grandparents, uncle, aunt) diagnosed with T2DM OR

          -  subject without any family history of T2DM.

        Exclusion Criteria:

          -  any prior history of obesity

          -  elevated triglyceride concentration (above 1.7 mmol/l)

          -  hypertension

          -  thyroid or other endocrine disease

          -  smoking

          -  drug abuse
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Stich, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third faculty of medicine, Charles University in Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michaela Siklova, PhD</last_name>
    <phone>+420 604 254 992</phone>
    <email>michaela.siklova@lf3.cuni.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lenka Rossmeislova, PhD</last_name>
    <phone>+420 267 102 211</phone>
    <email>lenka.rossmeislova@lf3.cuni.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Third Faculty of Medicine, Charles University</name>
      <address>
        <city>Prague</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela Siklova, PhD</last_name>
      <phone>+420 267 102 211</phone>
      <email>michaela.siklova@lf3.cuni.cz</email>
    </contact>
    <investigator>
      <last_name>Vladimir Stich, prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008 May;9(5):367-77. doi: 10.1038/nrm2391. Review.</citation>
    <PMID>18401346</PMID>
  </reference>
  <reference>
    <citation>Lu Q, Li M, Zou Y, Cao T. Induction of adipocyte hyperplasia in subcutaneous fat depot alleviated type 2 diabetes symptoms in obese mice. Obesity (Silver Spring). 2014 Jul;22(7):1623-31. doi: 10.1002/oby.20705. Epub 2014 Feb 11.</citation>
    <PMID>24435986</PMID>
  </reference>
  <reference>
    <citation>Alligier M, Gabert L, Meugnier E, Lambert-Porcheron S, Chanseaume E, Pilleul F, Debard C, Sauvinet V, Morio B, Vidal-Puig A, Vidal H, Laville M. Visceral fat accumulation during lipid overfeeding is related to subcutaneous adipose tissue characteristics in healthy men. J Clin Endocrinol Metab. 2013 Feb;98(2):802-10. doi: 10.1210/jc.2012-3289. Epub 2013 Jan 2.</citation>
    <PMID>23284008</PMID>
  </reference>
  <reference>
    <citation>Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, Curtis RK, Jimenez-Linan M, Blount M, Yeo GS, Lopez M, Seppänen-Laakso T, Ashcroft FM, Oresic M, Vidal-Puig A. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007 Apr 27;3(4):e64.</citation>
    <PMID>17465682</PMID>
  </reference>
  <reference>
    <citation>Rossmeislová L, Malisová L, Kracmerová J, Tencerová M, Kovácová Z, Koc M, Siklová-Vítková M, Viquerie N, Langin D, Stich V. Weight loss improves the adipogenic capacity of human preadipocytes and modulates their secretory profile. Diabetes. 2013 Jun;62(6):1990-5. doi: 10.2337/db12-0986. Epub 2013 Feb 1.</citation>
    <PMID>23378611</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2017</study_first_posted>
  <last_update_submitted>May 31, 2017</last_update_submitted>
  <last_update_submitted_qc>May 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charles University, Czech Republic</investigator_affiliation>
    <investigator_full_name>Vladimir Stich</investigator_full_name>
    <investigator_title>Professor, MUDr</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>adipose tissue</keyword>
  <keyword>preadipocytes</keyword>
  <keyword>expandability</keyword>
  <keyword>hypertrophy</keyword>
  <keyword>hyperplasia</keyword>
  <keyword>lipogenesis</keyword>
  <keyword>adipogenesis</keyword>
  <keyword>insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

